Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial
Key Points
Ivarmacitinib significantly enhances quality of life in patients with moderate-to-severe atopic dermatitis, and improves sleep quality.
The post hoc analysis from a phase III trial indicated improvements in working productivity among those treated with ivarmacitinib.
Phase III trial data highlighted the effectiveness of ivarmacitinib as a selective Janus kinase-1 inhibitor for atopic dermatitis.
Findings suggest that ivarmacitinib may offer substantial benefits beyond itch relief, impacting daily activities and overall well-being.
Abstract
Background Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).
Un soulagement précoce des démangeaisons avec ivarmacitinib améliore la qualité de vie, la productivité au travail et la qualité du sommeil chez les patients atteints de dermatite atopique modérée à sévère : une analyse post hoc d'un essai de phase III | Synapse